Download Cellular Cardiology

XCELLIGENCE SYSTEM CELLULAR
CARDIOLOGY PUBLICATION LIST
RELEVANT DATA, REMARKABLE PUBLICATIONS
Accelerate your research and increase your productivity with pioneering real -time cellular analysis
ARRYTHMIA & COMPOUND VALIDATION
1. Jonsson MK, Wang QD, Becker B. Impedance-based detection of beating rhythm and proarrhythmic
effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev Technol. 2011
Dec;9(6):589-99. (Roche R&D, Sweden)
2. Xi B, Wang T, Li N, Ouyang W, Zhang W, Wu J, Xu X, Wang X, Abassi YA. Functional cardiotoxicity profiling
and screening using the xCELLigenceRTCA Cardio System. J Lab Autom. 2011 Dec;16(6):415-21. (ACEA
Biosciences, Inc.,USA)
3. Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL. Estimating the risk of
drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
Toxicol Sci. 2011 Sep;123(1):281-9. (Hoffmann-La Roche, Nutley, USA.)
4. Nguemo F, Šarić T, Pfannkuche K, Watzele M, Reppel M, Hescheler J. In vitro model for assessing
arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol
Biochem. 2012;29(5-6):819-32. (University of Cologne, Germany)
5. Abassi YA, Xi B, Li N, Ouyang W, Seiler A, Watzele M, Kettenhofen R, Bohlen H, Ehlich A, Kolossov E, Wang X,
Xu X. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive
tool for preclinical safety assessment. Br J Pharmacol. 2012 Mar;165(5):1424-41. (ACEA Biosciences,
Inc.,USA)
6. Himmel HM. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse
cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):97111. (Bayer Pharma AG, Germany)
7. Guo L, Coyle L, Abrams RM, Kemper R, Chiao ET, Kolaja KL. Refining the human iPSC cardiomyocyte
arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. (Hoffmann-La Roche, Inc.,
Nutley, USA)
8. Nembo EN, Dimo T, Bopda OS, Hescheler J, Nguemo F. The proliferative and chronotropic effects of
Brillantaisia nitens Lindau (Acanthaceae) extracts on pluripotent stem cells and their
cardiomyocytes derivatives. J Ethnopharmacol. 2014 Oct 28;156:73-81. (University of Cologne, Germany)
9. Filomain Nguemo, Judith Semmler, and Jürgen Hescheler. Chapter 16: Label-Free Impedance
Measurements for Profiling Drug- Induced Cardiotoxicity in Label-Free Biosensor Methods in Drug
Discovery 2015 (University of Cologne, Germany)
Page 1 of 5
Cell lines used:
Human iPSC iCELL cardiomyocyte (Cellular Dynamics International), mouse ESC Cor.At cardiomyocytes
(Axiogenesis), rat neonatal cardiomyocyte, murine ES D3 -pig44 derived cardiomyocyte, mouse iPS derived
cardiomyocyte (University of cologne),
Compounds tested: 98 cpds
Acetamidophenol, Aconitine, Ajmaline (IV), Alfuzosin, Alpidem, Amiodarone, Amlodipine,Amitriptyline,
Amoxicillin, Amphotericin B, Arsenic trioxide, Aspirin, Astemizole, Atenolol, ATX-II, Bay K 8644, Bepridil,
Blebbistatin, Brillantaisia nitens extract(BNE), Carbachol, Captopril, Cetirizine, Chromanol 293B,
Chlorpromazine, Cibenzoline, Cisapride, Clarithromycin, Clozapine, Colchicine, Crizotinib, Cyclophosphamide,
Cyclosporin A, Dalfampridine, Dantrolene, Desipramine, Dexrazoxane, Digitoxin, Digoxin, Diltiazem,
Diphenhydramine, Dobutamine, Dofetilide, Doxorubicin, E-4031, Epirubicin, Erythromycin, Flecainide,
Fluorouracil, Fluoxetine, Fluvoxamine, Geldanamycin, Heptanol, HMR1556, Idarubicin, Imatinib, Imipramine,
Isoprenaline, Isoproterenol, Isradipine, Jaspamide, Ketoconazole, Levosimendan, Lidocaine (IV), Loratadine,
Mechlorethamine, Mexiletine, Mibefradil, Mitoxantrone, Moxifloxacin, Nefazodone, Nifedipine, Nilotinib,
Nimesulide, Nitrendipine, Olanzipine, Ouabain, Pentamidine, Quinidine, Ranolazine, RO5657, Rofecoxib, Sotalol,
Sunitinib, Terfenadine, Thioridazine, Tetrodotoxin (TTX), Verapamil, Zetebradine,
KINASE & CONTRACTILITY
1. Peters MF, Scott CW, Ochalski R, Dragan YP. Evaluation of cellular impedance measures of
cardiomyocyte cultures for drug screening applications. Assay Drug Dev Technol. 2012 Dec;10(6):52532. (AstraZeneca Pharmaceuticals, USA)
2. Lamore SD, Kamendi HW, Scott CW, Dragan YP, Peters MF. Cellular impedance assays for predictive
preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicol Sci. 2013 Oct;135(2):40213. (AstraZeneca, USA)
3. Scott CW, Zhang X, Abi-Gerges N, Lamore SD, Abassi YA, Peters MF. An impedance-based cellular assay
using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol
Sci. 2014 Dec;142(2):331-8. (AstraZeneca Pharmaceutical, USA)
4. Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL. Human stem cell-derived cardiomyocytes in cellular
impedance assays: bringing cardiotoxicity screening to the front line. Cardiovasc Toxicol. 2015
Apr;15(2):127-39. (AstraZeneca Pharmaceutical, USA)
5. Lamore SD, Scott CW, Peters MF. Cardiomyocyte Impedance Assays in Assay Guidance Manual [Internet].
Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 20042015 Feb 25. (AstraZeneca Pharmaceutical, USA)
Cell lines used:
Human iPSC iCELL cardiomyocyte (Cellular Dynamics International), rat neonatal cardiomyocyte, rat neonatal
cardiomyocyte with transient siRNA (Chk1, Chk2 and Chk1+2) knockdowns,
Page 2 of 5
Compounds tested:
Amoxicillin, Captopril, Furosemide, Lapatinib, Paracetamol, Parvastatin, Atenolol, Bepridil, Chloroquine,
Clonidine, Doxorubicin, Flecainide, Haloperidol, Nifedipine, Quinidine, Verapamil, Digoxin, Dobutamine,
Epinephrine, Isoproterenol, Milrinone, Chk Inhibitors: AZD776, SCH900776, UCN-01, SB218078, PF477736,
CHIR-124, LY2603618, PD407824, NSC109555.
Compared to with dog cardiomyocyte sarcomere shortening assay (IonOptix): 52 compounds
Milrinone, Levosimendan, AZ3, Glibenclamide, AZ1, Digoxin, Dobutamine, Epinephrine, Isoproterenol, Sildenafil,
AZ7, AZ8, Phentolamine, Zimelidine, Lapatinib, Paracetamol, Amoxicillin, Aspirin , AZ2, Captopril, Cimetidine,
Enalapril, Furosemide, Lisinopril, Pravastatin, Ramipril, Ranitidine, Tolbutamide, Atenolol, Clonidine,
Doxorubicin, AZ10, AZ11, Amitriptyline , AZ4, Bepridil, Chloroquine, Flecainide, AZ12, AZ6, AZ9, Cibenzoline,
Diltiazem, Disopyramide, Haloperidol , Nifedipine, Quinidine, Sunitinib, Verapamil
ONCOLOGY DRUGS WITH SHORT- & LONG-TERM TOX
1. Schweikart K, Guo L, Shuler Z, Abrams R, Chiao ET, Kolaja KL, Davis M. The effects of jaspamide
on human cardiomyocyte function and cardiac ion channel activity. Toxicol In Vitro. 2013
Mar;27(2):745-51. (National Cancer Institute, USA)
2. Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S. Multiparameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human
cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55. (Quintiles, USA)
3. Eldridge S, Guo L, Mussio J, Furniss M, Hamre J 3rd, Davis M. Examining the protective role of ErbB2
modulation in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2014
Oct;141(2):547-59. (National Cancer Institute, USA)
4. Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S. A multi-parameter in vitro screen in
human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional
cardiac toxicity. Toxicol Sci. 2015 Jan;143(1):147-55. (Quintiles Inc., USA)
5. Doherty KR, Talbert DR, Trusk PB, Moran DM, Shell SA, Bacus S. Structural and functional screening in
human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of
multiple drug types. Toxicol Appl Pharmacol. 2015 May 15;285(1):51-60. (Quintiles Inc., USA)
6. Guo L, Eldridge S, Furniss M, Mussio J, Davis M. Use of Human Induced Pluripotent Stem Cell-Derived
Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.
Curr Protoc Chem Biol. 2015 Sep 1;7(3):141-85. (Frederick National Laboratory for Cancer Research, USA)
Cell lines used:
Human iPSC iCELL cardiomyocyte (Cellular Dynamics International), rat neonatal cardiomyocyte, rat neonatal
cardiomyocyte with transient siRNA (Chk1, Chk2 and Chk1+2) knockdowns
Page 3 of 5
Reagents tested:
Amiodarone, Amoxicillin, AraC, Aspirin, Astemizole, Atorvastatin, Blebbistatin, Captopril, Cisapride, Crizotinib,
Daunorubicin, Dofetilide, Doxorubicin, Erlotinib, Imatinib, Isoproterenol, Jaspamide, Mitoxantrone, Neuregulin1, Nilotinib, Nifedipine, Ponatinib, Rofecoxib, Rosiglitazone, Sotalol, Sorafenib, Sunitinib, Terfenadine,
Thioridazine, Trastuzumab, Verapamil
IPSC & DISEASE MODELS
1. Bornholz B, Weidtkamp-Peters S, Schmitmeier S, Seidel CA, Herda LR, Felix SB, Lemoine H, Hescheler J,
Nguemo F, Schäfer C, Christensen MO, Mielke C, Boege F. Impact of human autoantibodies on β1adrenergic receptor conformation, activity, and internalization. Cardiovasc Res. 2013 Mar 1;97(3):47280. (University Hospital, Germany)
2. Traister A, Li M, Aafaqi S, Lu M, Arab S, Radisic M, Gross G, Guido F, Sherret J, Verma S,Slorach C, Mertens L,
Hui W, Roy A, Delgado-Olguín P, Hannigan G, Maynes JT, Coles JG. Integrin-linked kinase mediates force
transduction in cardiomyocytes by modulating SERCA2a/PLN function. Nat Commun. 2014 Sep
11;5:4533. (Hospital for Sick Children, Canada)
3. Han L, Li Y, Tchao J, Kaplan AD, Lin B, Li Y, Mich-Basso J, Lis A, Hassan N, London B, Bett GC, Tobita K,
Rasmusson RL, Yang L. Study familial hypertrophic cardiomyopathy using patient-specific induced
pluripotent stem cells. Cardiovasc Res. 2014 Nov 1;104(2):258-69. (University of Pittsburgh School of
Medicine, USA)
Cell lines used:
Human iPSC iCELL cardiomyocyte (Cellular Dynamics International), Patient-specific iPSC cardiomyocytes
(female diagnosed with cardiac hypertrophy, MYH7 C1324G), Transgentic mouse iPSC cardiomyocytes (ILKWT
and ILKR211A)
Reagents tested:
Doxorubicin, IgG (from healthy individuals), IgG (from in patients with dilated cardiomyopathy (DCM))
HYPERTROPHY
1. Sin YY, Edwards HV, Li X, Day JP, Christian F, Dunlop AJ, Adams DR, Zaccolo M, Houslay MD, Baillie GS.
Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist
induced hypertrophic response in cardiac myocytes. J Mol Cell Cardiol. 2011 May;50(5):872-83.
(University of Glasgow, UK)
Page 4 of 5
Cell lines used:
Neonatal Cardiomyocytes
Reagents tested:
Isoproterenol, peptide 906 (disrupt PDE4-HSP20 complex)
STRUCTURAL TOX
1. Saggiomo SL, Seymour JE. Cardiotoxic effects of venom fractions from the Australian box jellyfish
Chironex fleckeri on human myocardiocytes. Toxicon. 2012 Sep 1;60(3):391-5. (James Cook University,
Australia)
2. Chaousis S, Smout M, Wilson D, Loukas A, Mulvenna J, Seymour J. Rapid short term and gradual
permanent cardiotoxic effects of vertebrate toxins from Chironex fleckeri (Australian box jellyfish)
venom. Toxicon. 2014 Mar;80:17-26. (James Cook University, Australia)
Cell lines used:
Human Cardiac Myocytes (HCM, ScienCellTM) and Human Skeletal Muscle cells (HSkMC, ScienCellTM)
Reagents tested:
Venom fractions from the Australian box jellyfish
Page 5 of 5